abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

CB1R
Back
Total number of drugs
209
Phase II and later clinical stages
12.9%
Involving companies
150
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
CXB-006CXB-006Small molecule drugEye DiseasesCannabinoid CB1 receptor agonistsPharmaNess NeuroscienceDiscontinuedCXB-006
detail  >
INDV-5004INDV-5004Small molecule drugOther DiseasesCannabinoid CB1 receptor antagonistsIndivior Ltd.PreclinicalINDV-5004
detail  >
IbipinabantIbipinabantSmall molecule drugEndocrinology and Metabolic DiseaseCannabinoid CB1 receptor antagonistsAbbVie, Inc.Phase 2/3Ibipinabant
detail  >
HT-005 Z-PodsHT-005 Z-PodsChemical drugsImmune System Diseases Skin and Musculoskeletal Diseases Other DiseasesCannabinoid CB1 receptor agonists Cannabinoid CB2 receptor agonistsZylö Therapeutic, Inc.PreclinicalHT-005 Z-Pods
detail  >
Dianicline/RimonabantDianicline/RimonabantSmall molecule drugOther DiseasesCannabinoid CB1 receptor antagonists Neuronal acetylcholine receptor; alpha4/beta2 agonistsSanofiDiscontinuedDianicline/Rimonabant
detail  >
CXB-040CXB-040Small molecule drugEye DiseasesCannabinoid CB1 receptor agonistsPharmaNess NeuroscienceDiscontinuedCXB-040
detail  >
CXB-029CXB-029Small molecule drugNervous System Diseases Endocrinology and Metabolic Disease Eye Diseases Other DiseasesCannabinoid CB1 receptor antagonistsPharmaNess NeuroscienceDiscontinuedCXB-029
detail  >
CCT-717CCT-717siRNAEndocrinology and Metabolic DiseaseCannabinoid CB1 receptor antagonists TLE family member 3, transcriptional corepressor inhibitors RNA interferenceCanary Cure Therapeutics Inc.PreclinicalCCT-717
detail  >
CMX-020CMX-020Small molecule drugNervous System Diseases Other DiseasesCannabinoid CB1 receptor modulators Cannabinoid CB2 receptor modulatorsCytometix, Inc.Phase 2CMX-020
detail  >
CP-741952CP-741952Small molecule drugEndocrinology and Metabolic DiseaseCannabinoid CB1 receptor antagonistsPfizer Inc.Phase 2CP-741952
detail  >
Total 209 data
1
2
3
4
5
6
...
20
21